ONO PHARMACEUTICAL CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: $7.1B

Website: https://www.ono.co.jp/

Clinical Trials

A Study of ONO-7475 in Patients With Acute Leukemias

Phase 1

Terminated

Conditions: Acute Leukemia
Myelodysplastic Syndromes

Interventions: Drug: ONO-7475 6mg once daily
Drug: ONO-7475 3mg once daily
Drug: ONO-7475 10mg once daily
Drug: ONO-7475 6mg + Venetoclax (70-400mg)

First Posted Date: 2017-06-05

Last Posted Date: 2024-07-15

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 42

Registration Number: NCT03176277

Locations: 🇺🇸
The Ohio State University (OSU), Columbus, Ohio, United States
🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 13 locations

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: ONO-4578
Drug: ONO-4538

First Posted Date: 2017-05-16

Last Posted Date: 2024-08-23

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 183

Registration Number: NCT03155061

Locations: 🇯🇵
Aichi Clinical Site 1, Nagoya, Aichi, Japan
🇯🇵
Osaka Clinical Site 4, Takatsuki, Osaka, Japan
🇯🇵
Aichi Clinical Site 2, Toyoake, Aichi, Japan

and more 19 locations

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: ONO-4538
Drug: Carboplatin
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Placebo

First Posted Date: 2017-04-17

Last Posted Date: 2024-05-06

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 550

Registration Number: NCT03117049

Locations: 🇰🇷
Chungcheongbuk-do Clinical Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇯🇵
Aichi Clinical Site, Toyoake, Aichi, Japan
🇯🇵
Aichi Clinical Site2, Nagoya, Aichi, Japan

and more 81 locations

Study of ONO-8577 in Patients With Overactive Bladder

Phase 2

Completed

Conditions: Overactive Bladder

Interventions: Drug: ONO-8577
Drug: Placebo
Drug: solifenacin succinate + mirabegron

First Posted Date: 2017-04-10

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 207

Registration Number: NCT03106623

Locations: 🇯🇵
Gunma Clinical Site 02, Maebashi, Gunma, Japan
🇯🇵
Hyogo Clinical Site 02, Akashi, Hyogo, Japan
🇯🇵
Gunma Clinical Site 01, Takasaki, Gunma, Japan

and more 27 locations

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Nivolumab
Drug: Tegafur-gimeracil-oteracil potassium
Drug: Oxaliplatin
Drug: Placebo
Drug: Capecitabine

First Posted Date: 2016-12-30

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 800

Registration Number: NCT03006705

Locations: 🇨🇳
Anhui Province Clinical Site, Anhui Province, China
🇨🇳
Zhejiang Province Clinical Site, Zhejiang Province, China
🇯🇵
Nagano Clinical Site, Saku, Nagano, Japan

and more 89 locations

A Study to Evaluate ONO-4474 in Patients With Pain Due to Osteoarthritis of the Knee

Phase 2

Terminated

Conditions: Osteoarthritis, Knee
Pain

Interventions: Drug: ONO-4474
Drug: Placebo matching ONO-4474

First Posted Date: 2016-12-20

Last Posted Date: 2018-02-26

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 70

Registration Number: NCT02997696

Locations: 🇬🇧
Investigational Site, Romford, United Kingdom
🇵🇱
Investigational Site 4808, Bialystok, Poland
🇵🇱
Investigational Site 4818, Bialystok, Poland

and more 16 locations

Study of ONO-4538 in Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: ONO-4538
Drug: Oxaliplatin
Drug: Tegafur- Gimeracil-Oteracil potassium
Drug: Capecitabine
Drug: Placebo

First Posted Date: 2016-04-21

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 680

Registration Number: NCT02746796

Locations: 🇯🇵
Tokyo Clinical Site2, Shinjuku-ku, Tokyo, Japan
🇨🇳
Tainan Clinical Site1, Tainan, Taiwan
🇨🇳
Tainan Clinical Site2, Tainan, Taiwan

and more 94 locations

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Advanced Non-small Cell Lung Cancer

Interventions: Drug: ONO-4538

First Posted Date: 2015-10-21

Last Posted Date: 2022-04-27

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 53

Registration Number: NCT02582125

Locations: 🇨🇳
Tainan Clinical Site 1, Tainan, Taiwan
🇨🇳
Taichung Clinical Site 2, Taichung, Taiwan
🇨🇳
Tainan Clinical Site 2, Tainan, Taiwan

and more 5 locations

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Phase 3

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Docetaxel/Paclitaxel
Drug: Nivolumab

First Posted Date: 2015-10-06

Last Posted Date: 2022-07-06

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 419

Registration Number: NCT02569242

Locations: 🇺🇸
Orlando Health, Inc, Orlando, Florida, United States
🇺🇸
Georgetown University Med Ctr, Washington, District of Columbia, United States
🇩🇪
Universitatsklinikum Jena, Innere Medizin II, Jena, Germany

and more 55 locations

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers

Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Drug: ONO-4474 Part A1
Drug: ONO-4474 Part A2
Drug: Placebo Part A2
Drug: Placebo Part B
Drug: Placebo Part A1
Drug: Placebo Part C
Drug: ONO-4474 Part B
Drug: ONO-4474 Part D
Drug: Placebo Part D
Drug: ONO-4474 Part C

First Posted Date: 2015-05-27

Last Posted Date: 2016-06-30

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 141

Registration Number: NCT02454387

Locations: 🇬🇧
Nottingham Clinical SIte, Nottingham, United Kingdom
🇩🇰
Aalborg Clinical Site, Aalborg, Denmark

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy